

2nd edition

Unmet challenges in high risk hematological malignancies: from benchside to clinical practice

Turin, May 20-21, 2021

Starhotels Majestic

Scientific board:

Marco Ladetto (Alessandria)

Umberto Vitolo (Candiolo-TO)



REQUESTED AUSPICES

AZIENDA OSPEDALIERO-UNIVERSITARIA

Città della Salute e della Scienza di Torino - Presidio Ospedaliero Le Molinette

ISTITUTO DI CANDIOLO - IRCCS

OSPEDALE CIVILE SS. ANTONIO E BIAGIO E CESARE ARRIGO

UNIVERSITÀ DI TORINO

FIL - Fondazione Italiana Linfomi

GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo,
cellule staminali emopoietiche e terapia cellulare

SIE - Società Italiana di Ematologia

SIES - Società Italiana di Ematologia Sperimentale

RETE ONCOLOGICA DEL PIEMONTE E DELLA VALLE D'AOSTA

FACULTY

Emanuele	Angelucci	Genoa, Italy	Alessandra	Larocca	Turin, Italy
Stephen M.	Ansell	Rochester, USA	Maurizio	Martelli	Rome, Italy
Hervé	Avet Loiseau	Toulouse, France	Massimo	Massaia	Cuneo, Italy
Monica	Balzarotti	Rozzano (MI), Italy	Francesco	Merli	Reggio Emilia, Italy
Renato	Bassan	Mestre (VE), Italy	Grzegorz S.	Nowakowski	Rochester, USA
Mario	Boccardo	Turin, Italy	Owen A.	O'Connor	New York, USA
Alan K.	Burnett	Glasgow, UK	Fabrizio	Pane	Naples, Italy
Angelo Michele	Carella	Genoa, Italy	Stefano A.	Pileri	Milan, Italy
Annalisa	Chiappella	Milan, Italy	Antonio	Pinto	Naples, Italy
Daniela	Cilloni	Orbassano (TO), Italy	Christiane	Pott	Kiel, Germany
Antonio	Cuneo	Ferrara, Italy	Patrizia	Pregno	Turin, Italy
Barbara	Eichhorst	Cologne, Germany	Alessandro	Rambaldi	Bergamo, Italy
Brunangelo	Falini	Perugia, Italy	Luigi	Rigacci	Rome, Italy
Simone	Ferrero	Turin, Italy	Giuseppe	Saglio	Turin, Italy
Robin	Foà	Rome, Italy	Gilles	Salles	New York, USA
Nathan H.	Fowler	Houston, USA	Valeria	Santini	Florence, Italy
Gianluca	Gaidano	Novara, Italy	Stephen J.	Schuster	Philadelphia, USA
Paolo	Ghia	Milan, Italy	Michele	Spina	Aviano (PN), Italy
Paola	Guglielmelli	Florence, Italy	Enrico	Tiacci	Perugia, Italy
Olivier	Hermine	Paris, France	Jan	Trka	Prague, Czech Republic
Peter	Hillmen	Leeds, UK	Adriano	Venditti	Rome, Italy
Martin	Hutchings	Copenhagen, Denmark	Carlo	Visco	Verona, Italy
Nicolaus	Kröger	Hamburg, Germany	Umberto	Vitolo	Candiolo (TO), Italy
Marco	Ladetto	Alessandria, Italy	Elena	Zamagni	Bologna, Italy
			Emanuele	Zucca	Bellinzona, Switzerland

- 09.00 **Welcome and introduction**
M. Ladetto, U. Vitolo and Local Scientific Authorities
- 09.30-11.00 **Hodgkin Lymphoma and T-cell Lymphoma**
Chairmen: A. Pinto, M. Spina
- 09.30 Genetics and biology of classical Hodgkin Lymphoma: clinical implications
E. Tiacci
- 09.50 How I treat high risk Hodgkin Lymphoma
S.M. Ansell
- 10.10 Histopathology and molecular biology of T-cell Lymphoma
S.A. Pileri
- 10.30 How I treat high risk T-cell Lymphomas
O.A. O'Connor
- 10.50 Panel Discussion
- 11.00-11.15 *Coffee Break*

- 11.15-11.45 **LECTURE I**
Chairman: M. Ladetto
Optimizing outcomes for CD19-directed CAR-T cell therapy in refractory B-cell lymphomas
S.J. Schuster
- 11.45-13.00 **Mantle Cell Lymphoma**
Chairmen: M. Ladetto, M. Martelli
- 11.45 Biological identification of high risk Mantle Cell Lymphoma
C. Pott
- 12.05 How I treat high risk Mantle Cell Lymphoma in first line
O. Hermine
- 12.25 How I treat relapsed/refractory Mantle Cell Lymphoma
C. Visco
- 12.45 Panel Discussion
- 13.00-14.00 *Lunch*

14.00-14.30 LECTURE II

Chairman: U. Vitolo

Impact of Lugano conferences in the lymphoma research

E. Zucca

14.30-16.00 Diffuse large B-Cell Lymphoma

Chairmen: M. Balzarotti, U. Vitolo

14.30 Biological identification of high risk DLBCL

G. Gaidano

14.50 How I treat high risk DLBCL in first line

A. Chiappella

15.10 How I treat DLBCL in relapse

G.S. Nowakowski

15.30 Novel antibodies in aggressive lymphomas

M. Hutchings

15.50 Panel Discussion

16.00-16.15 *Coffee Break*

16.15-17.25 Follicular Lymphoma

Chairmen: F. Merli, L. Rigacci

16.15 Biological of high risk Follicular Lymphoma

S. Ferrero

16.35 How I treat high risk Follicular Lymphoma in first line

G. Salles

16.55 How I treat relapsed/refractory Follicular Lymphoma

N.H. Fowler

17.15 Panel Discussion

17.25-18.35 Chronic Lymphocytic Leukemia

Chairmen: A. Cuneo, P. Ghia

17.25 Biology of high risk Chronic Lymphocytic Leukemia

M. Massaia

17.45 Defining high risk Chronic Lymphocytic Leukemia in 2021 from the clinician`s perspective

B. Eichhorst

18.05 How I treat relapsed/refractory Chronic Lymphocytic Leukemia

P. Hillmen

5 18.25 Panel Discussion

09.00-10.10 Multiple Myeloma

Chairmen: M. Boccadoro, M. Massaia

09.00 Biology of high risk Multiple Myeloma
H. Avet-Loiseau

09.20 How I treat young high risk Multiple Myeloma
E. Zamagni

09.40 How I treat elderly high risk Multiple Myeloma
A. Larocca

10.00 Panel Discussion

10.10-10.40 LECTURE III

Chairman: G. Saglio

Beyond 3+7 in Acute Myelogenous Leukemia
A.K. Burnett

10.40-11.00 *Coffee Break*

11.00-12.10 Myeloproliferative Disorders

Chairmen: A.M. Carella, G. Saglio

11.00 Biology of high risk myeloproliferative disorders
P. Guglielmelli

11.20 How I treat high risk Chronic Myeloid Leukemia
P. Pregnò

11.40 How I treat high risk myeloproliferative neoplasms
D. Cilloni

12.00 Panel Discussion

12.10-13.10 *Lunch*

13.10-14.20 Acute Lymphoblastic Leukemia and Transplantation

Chairmen: R. Foà, A. Rambaldi

- 13.10 Biology of High Risk Acute Lymphoblastic Leukemia
J. Trka
- 13.30 How I treat high risk Acute Lymphoblastic Leukemia in first line
R. Bassan
- 13.50 Allogeneic transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes
N. Kröger
- 14.10 Panel Discussion

14.20-15.45 Acute Myeloblastic Leukemia and Myelodysplastic Syndrome

Chairmen: E. Angelucci, F. Pane

- 14.20 Genomic identification of high risk Acute Myeloid Leukemia
B. Falini
- 14.40 How I treat high risk Myelodysplastic Syndromes
V. Santini
- 15.00 How I treat elderly Acute Myeloid Leukemia patients
A. Venditti
- 15.20 Panel Discussion
- 15.30 Closing remarks
M. Ladetto, U. Vitolo

With an unrestricted educational grant of:

abbvie

astellas

Roche

AstraZeneca

Celgene

gsk

Janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

NOVARTIS

Takeda

AMGEN

GILEAD

Incyte

iQONE
HEALTHCARE GROUP

Pfizer Oncology

SANDOZ
A Novartis Division

GENERAL INFORMATION

MEETING VENUE

Starhotels Majestic

Corso Vittorio Emanuele II, 54
10123 Torino, Italy
Tel. +39 011 539153

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828- 282393.
- No. 9,1 CME credits for Physicians (Haematology, Oncology, Internal Medicine) and Biologists.
- Educational objective: "linee guida-protocolli-procedure".

OFFICIAL LANGUAGE

English

BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants and speakers will be given a badge which must be worn in order to be admitted to the scientific sessions. A certificate will be given to all participants at the end of the meeting.



The organization is proud to compensate its greenhouse gas emissions investing in the carbon offset project: "Mytrah Wind Power".

SCIENTIFIC BOARD

Marco Ladetto MD

Head of Hematology Division
S.S. Antonio e Biagio and Cesare Arrigo Hospital
Via Venezia, 16 - 15121 Alessandria, Italy

Umberto Vitolo MD

Hematology Consultant
Candiolo Cancer Institute - FPO-IRCCS
Strada Provinciale, 142 - 10060 Candiolo (TO), Italy

SCIENTIFIC COMMITTEE

Prof. Mario Boccadoro (Turin)

Prof. Gianluca Gaidano (Novara)

Prof. Massimo Massaia (Cuneo)

Prof. Giuseppe Saglio (Orbassano - TO)

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy
Phone +39 051 4210559 - Fax +39 051 4210174
E-mail: ercongressi@ercongressi.it
www.ercongressi.it